Compare Citius Pharmaceuticals Inc (CTXR) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs T Rowe Price Group Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.79M), while T Rowe Price Group Inc trades at $104.25 (market cap $22.20B). The key difference: T Rowe Price Group Inc is far larger — about 1609.9× Citius Pharmaceuticals Inc's market cap, and T Rowe Price Group Inc pays a 5% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and T Rowe Price Group Inc for 115 Days on average.
| CTXR | TROW | |
|---|---|---|
Market Cap | $13.79M | $22.20B |
Volume | 156,684 | 1,738,431 |
Sector | Health | Financials |
52-Week High | $1.82 | $121.68 |
52-Week Low | $0.48 | $86.19 |
Typical Hold Time | 16 Days | 115 Days |
Enterprise Value | $3.96M | $19.39B |
Dividend Yield | — | 5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
T. Rowe Price Group (TROW) trades at $104.07, up 0.45% with bearish technical signals but strong fundamentals including a 10.45 P/E ratio and 29.26% net margin. Recent earnings beat expectations in Q1 and Q2 2026, while Q4 2025 slightly missed. The company maintains robust cash flow with $704.4M net cash flow in 2025 and a dividend yield near 5% with 40 years of consecutive growth.
The stock offers value with attractive valuation metrics and consistent profitability, though technical indicators suggest near-term pressure. Key risks include market-sensitive revenue streams and net outflows, while analyst consensus at $112 target implies 7.6% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
